The Relative Strength (RS) Rating for Oric Pharmaceuticals entered a new percentile Monday, with an increase from 79 to 84.
Looking For The Best Stocks To Buy And Watch? Start Here
This proprietary rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks often have an RS Rating of over 80 as they begin their biggest climbs.
Oric Pharmaceuticals is working on a cup with handle with an 11.27 buy point. See if the stock can break out in heavy trade.
The company posted 0% earnings growth in the latest quarterly report. Sales rose 0%.
Oric Pharmaceuticals holds the No. 245 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
